Document:

exv10w12

 

Exhibit 10.12

NUCRYST PHARMACEUTICALS CORP.

RESTRICTED STOCK UNIT AWARD AGREEMENT

GRANT of Restricted Stock Units made effective as of ######## (the “Grant Date”)

	 	 	 
	TO:

	 	## (the “Participant”)
	 
	 	 
	BY:

	 	NUCRYST Pharmaceuticals Corp. (the “Company”)

     WHEREAS, on December 21, 2005, the Board of Directors of the Company (the “Board”) approved
and adopted the Company’s 1998 Equity Incentive Plan (as amended) (the “Plan”) and the Plan was
subsequently approved by the Toronto Stock Exchange; and

     WHEREAS, by resolution of the Board made on ########, the Board granted the Restricted Stock
Unit award provided for herein to the Participant, such grant to be effective the Grant Date and
subject to the terms set forth herein;

     NOW THEREFORE, in consideration of the mutual covenants hereinafter set forth, the parties
hereto agree as follows:

	1.	 	Equity Incentive Plan

The grant by the Company to the Participant of Restricted Stock Units by this Agreement is made
pursuant to the terms and conditions of the Plan. This Agreement and the terms and conditions of
the grant of Restricted Stock Units are subject in all respects to the terms and conditions of the
Plan, which is made a part of this Agreement. The Participant, by acceptance of this Agreement,
agrees to be bound by the Plan (and any regulations that may be established under the Plan) and
acknowledges receipt of a copy of the Plan and this Agreement. Terms that are defined in the Plan
and not otherwise defined in this Agreement shall have the same meaning when used in this Agreement
as in the Plan.

	2.	 	Grant of Restricted Stock Units

The Company hereby grants to the Participant, effective as of the Grant Date, #### Restricted Stock
Units (defined in the Plan and this Agreement as “Restricted Stock Units” or individually as a
“Restricted Stock Unit”), subject to the terms and conditions of this Agreement and the Plan.

	3.	 	Vesting

Unless otherwise set forth in this Agreement, the Restricted Stock Units shall vest:

	 	(a)	 	as to one third (1/3) on the first anniversary of the Grant Date;
	 
	 	(b)	 	as to one third (1/3) on the second anniversary of the Grant Date; and
	 
	 	(c)	 	as to one third (1/3) on the third anniversary of the Grant Date.

	4.	 	Restrictions

	 	(a)	 	No portion of the Restricted Stock Units or rights granted hereunder may be
sold, exchanged, transferred, assigned, pledged, hypothecated, or otherwise encumbered
or disposed of by the Participant, whether voluntarily, involuntarily or by operation
of law (collectively, “Prohibited Dispositions”) until such portion of the Restricted
Stock Units becomes vested and are paid out in accordance with Section 6 of this
Agreement.

 

 

	 	(b)	 	If the Participant ceases to be employed by the Company for any reason
whatsoever before all of the Restricted Stock Units have vested in accordance with
Section 3, then the vesting of all Restricted Stock Units shall stop immediately upon
the Termination Date, and the balance of the Restricted Stock Units subject to the
provisions of this Agreement which have not vested as of the Termination Date shall be
forfeited automatically without further notice to the Participant and no compensation
shall be paid therefore.

	5.	 	Issuance of Common Shares

As soon as reasonably practicable after Restricted Stock Units become vested as described in
Section 3, the Company shall register the name of the Participant as the owner of the Common Shares
with respect to which the vested Restricted Stock Units relate and subject to applicable
withholding of taxes, deliver one or more unlegended stock certificates in respect of the
Restricted Stock Units to the Participant. Notwithstanding any other provision of this Agreement,
all amounts payable to, or in respect of, the Participant in respect of Restricted Stock Units
shall be paid within three (3) years following the end of the year in which the Restricted Stock
Units were granted.

	6.	 	Rights as a Stockholder — Dividends

The Participant shall not have any rights or be entitled to exercise any voting rights, receive
dividends, or have or be entitled to any other rights as a shareholder in respect of any Restricted
Stock Units, other than the right to receive such Common Shares upon the vesting of the Restricted
Stock Units.

	7.	 	Distributions and Adjustments

If there is any change in the number or character of the Common Shares (through merger,
consolidation, reorganization, recapitalization, stock split, stock dividend, or otherwise), prior
to the vesting of the Restricted Stock Units, the Participant shall receive such number and type of
securities or other consideration on the same basis and at the same time as other shareholders,
provided that such securities or other consideration shall be subject to the same vesting
provisions, if any, as the Restricted Stock Units to which such securities or other consideration
relate.

	8.	 	Beneficiary

The Participant may file with the Company a written designation of a beneficiary on such form as
may be prescribed by the Company and may, from time to time, amend or revoke such designation. If
no designated beneficiary survives the Participant, the executor or administrator of the
Participant’s estate shall be deemed to be the Participant’s beneficiary.

	9.	 	General Matters

	 	(a)	 	Restricted Stock Units are not transferable or assignable
	 
	 	(b)	 	This Agreement is not an employment contract and nothing in this Agreement
shall be deemed to create in any way whatsoever any obligation on the Participant’s
part to continue to work for the Company (or any subsidiary of the Company), or of the
Company (or any subsidiary of the Company) to continue to employ the Participant.
	 
	 	(c)	 	This Agreement and the Plan constitute the entire agreement between the parties
relating to the grant of Restricted Stock Units to the Participant herein and
supersedes all prior communications, representations and negotiations in respect
thereto provided that, for greater certainty, in the event of any inconsistencies as
between this Agreement and the Plan, such matters shall be governed by the terms and
provisions of the Plan.
	 
	 	(d)	 	For the grant of the Restricted Stock Units to be effective, this Agreement
must be executed by the Participant and returned to the Company.

 

 

	 	(e)	 	The Participant acknowledges that the Company may be required to disclose to
the securities regulatory authorities, the Exchange or other regulatory authorities
duly authorized to make such request, the name, address and telephone number of the
Participant, the number of Restricted Stock Units granted, and if required by
applicable securities legislation, regulations, rules, policies or orders or by any
securities commission, the Exchange or other regulatory authority, it will, in a timely
manner, execute, deliver, file and otherwise assist the company in filing, such
reports, undertakings, and other documents with respect to the Restricted Stock Units
as may be required or requested by the Company to enable the Company to comply with
applicable securities legislation, regulations, rules, policies or orders or the
requirements of any securities commission or other regulatory authority or the
Exchange.
	 
	 	(f)	 	Time shall be of the essence of this Agreement.
	 
	 	(g)	 	This Agreement shall be governed by the laws of the Province of Alberta. The
parties agree that any disputes under this Agreement shall be resolved by the courts of
Alberta and each of the parties irrevocably attorn to the non-exclusive jurisdiction
thereof with respect to all such matters and the transactions contemplated herein.
	 
	 	(h)	 	The Participant acknowledges that neither the Plan or this Agreement restricts
the Company’s ability to conduct its business (including, but not limited to, such
decisions as transactions with related parties, new product development efforts,
cancellation of existing products, mergers and acquisitions, or corporate dissolution)
regardless of the effect those decisions may have on the value of Restricted Stock
Units.

The Company and the Participant have executed this Agreement on the ~ day of ~, 2007, to be
effective on the Grant Date.

NUCRYST PHARMACEUTICALS CORP.

	 	 	 	 	 
	By:
	 	 	 	 
	 

	 	 
	 	 
	 

	 	#######
	 	Participantexv10w4

 

Exhibit 10.4

Summary of Verbal Amendments, effective July 1, 2007, to Employment Agreement between Registrant
and Dr. Katherine J. Turner

Effective July 1, 2007, Dr. Turner’s base salary was increased to $220,000 and the payout ranges
applicable Dr. Turner’s base salary under the Company’s variable pay program were amended to 20% at
threshold, 40% at target and 70% at stretch.exv10w6

 

Exhibit 10.6

Summary of Termination of Employment Arrangement with Mr. B.M. Heck

Effective August 22nd, 2007, the Company verbally terminated the employment arrangement with Mr.
B.M Heck as Executive Chair of the Board such that, effective August 22, 2007, Mr. Heck was no
longer entitled to compensation of $20,000 per month or benefits he was previously paid as an
executive of the Company. Following the termination of the employment arrangement, Mr. Heck
immediately became entitled to Directors fees as an non-employee director in accordance with the
Company’s Director Compensation Plan.exv10w7

 

Exhibit 10.7

Gillis Separation Agreement

CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE

     This CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE (this “Agreement”) is entered into
as of this 22nd day of August 2007, by and between Scott H. Gillis (hereinafter “MR. GILLIS”),
NUCRYST Pharmaceuticals Inc., a Delaware Corporation, and NUCRYST Pharmaceuticals Corp., an Alberta
corporation (hereinafter collectively referred to as “NUCRYST”).

     WHEREAS, MR. GILLIS has been employed by NUCRYST in the Commonwealth of Massachusetts pursuant
to that certain Employment Agreement (the “Employment Agreement”), dated as of the 6th
day of December 1999, made by and between MR. GILLIS and Westaim Biomedical Inc., the predecessor
corporation to NUCRYST; and

     WHEREAS, MR. GILLIS executed an Employee Confidentiality Agreement (the “Confidentiality
Agreement”), dated as of the 6th day of December 1999, made by and between MR. GILLIS and Westaim
Biomedical Inc., the predecessor corporation to NUCRYST; and

     WHEREAS, both the Employment Agreement and the Confidentiality Agreement contain
post-employment restrictions; and

     WHEREAS, NUCRYST has decided to make a management and board leadership change, and NUCRYST and
MR. GILLIS desire to terminate amicably MR. GILLIS’S employment with NUCRYST and MR. GILLIS wishes
to resign from the board of directors as part of this change in strategic direction; and

 

 

     WHEREAS, MR. GILLIS is entitled to certain amounts and benefits provided in his Employment
Agreement upon the termination of his employment in the absence of this Agreement; and

     WHEREAS, in this Agreement, in consideration of the mutual promises contained herein, NUCRYST
has offered MR. GILLIS certain separation payments and benefits in lieu of, and greater than, the
amounts and benefits provided under the Employment Agreement;

     IT IS HEREBY AGREED by and between MR. GILLIS and NUCRYST as follows:

     1. The following provisions describe the termination of MR. GILLIS’S employment with NUCRYST
and the transition of his duties and responsibilities:

          a. MR. GILLIS acknowledges and agrees that his employment with NUCRYST will be permanently and
irrevocably severed including, but not limited to, resigning from the board of directors of
NUCRYST, effective August 22, 2007 (“Termination Date”), and that NUCRYST has no obligation,
contractual or otherwise, to hire, rehire or re-employ MR. GILLIS in the future. The Termination
Date shall be the date of the “qualifying event” under the Consolidated Omnibus Budget
Reconciliation Act of 1985 (“COBRA”) and, except as detailed in this Agreement, MR. GILLIS’S
eligibility to participate in NUCRYST’S benefits programs ends on the Termination Date. MR. GILLIS
will receive wages for all work performed by him from the last pay period prior to August 22, 2007
through the Termination Date, and all unused vacation pay, if any, less any applicable payroll
withholdings, in a paycheck to be issued to him on the next regular pay date on or after his
Termination Date. MR. GILLIS’S rights and obligations with regard to any vested Options and/or
vested Restricted Stock Options he may have as of the Termination Date, including his right to
exercise any of those vested Options

-2-

 

and/or Restricted Stock Options after the Termination Date, shall be governed by the terms and
conditions set forth in: the 1999 Stock Option Agreement, executed by MR. GILLIS on December 6,
1999 (the “1999 Option Agreement”); the 2002 letter amendment to the 1999 Option Agreement,
executed by MR. GILLIS on May 20, 2002 (the “Amendment to the 1999 Option Agreement”); the 2002
Stock Option Agreement, executed by MR. GILLIS on February 6, 2002 (the “2002 Option Agreement”);
the 2003 Stock Option Agreement, executed by MR. GILLIS on February 28, 2003 (the “2003 Option
Agreement”); the 2007 Stock Option Award Agreement, executed by MR. GILLIS on May 18, 2007 (the
“2007 Option Agreement”); and, the Restricted Stock Unit Award Agreement, executed by MR. GILLIS on
May 18, 2007 (the “RSU Agreement”). For the purposes of MR. GILLIS’S right to exercise any of
those vested Options and/or Restricted Stock Options, the provisions relating to termination for
reasons other than Just Cause shall apply.

          b. MR. GILLIS agrees that for the six (6) month period of time from his Termination Date on
August 22, 2007 to February 22, 2008 (the “Transition Period”), he will use good faith, reasonable
efforts to achieve an orderly transition of his duties, that he will cooperate with NUCRYST’s
transition efforts and that he will make himself available as requested by NUCRYST for consultation
with NUCRYST regarding matters which arise out of or relate to his duties and responsibilities with
NUCRYST.

     2. MR. GILLIS, on behalf of himself, his heirs, executors, administrators, and/or assigns, for
and in consideration of the undertakings of NUCRYST set forth herein, and intending to be legally
bound, does hereby release and forever discharge NUCRYST Pharmaceuticals Corp., Westaim Biomedical
Inc. and The Westaim Corporation, together with their parent and subsidiaries, affiliates,
predecessor and successor corporations and business

-3-

 

entities, joint ventures, and partners, past, present and future, and its and their agents,
directors, officers, employees, stockholders, investors, insurers and reinsurers, assigns,
representatives, and attorneys, past, present and future, and its and their assigns, heirs,
executors, and administrators, past, present, and future (collectively, the “Releasees”), of and
from any and all legally waivable causes of action, suits, debts, complaints, claims and demands
whatsoever in law or in equity, whether known or unknown, suspected or unsuspected, which MR.
GILLIS, or his heirs, executors, administrators, and assigns, ever had or now has against each or
any of the Releasees, from the beginning of time to the date of execution of this Agreement,
including, without limitation, any and all claims relating to MR. GILLIS’S employment with NUCRYST
or the termination of that employment, including, without limitation, claims under the Age
Discrimination in Employment Act, the Older Workers Benefit Protection Act, Title VII of the Civil
Rights Act of 1964, Section 1981 of the Civil Rights Act of 1870, the Americans with Disabilities
Act, the Family Medical Leave Act, the Employee Retirement Income Security Act, M.G.L. c. 151B, and
any and all other federal, state or local statutory or common law claims, now or hereafter
recognized, including but not limited to, any claims for economic loss, compensatory damages,
punitive damages, liquidated damages, attorneys’ fees, expenses and costs. MR. GILLIS represents
that he does not have any lawsuits, claims, or charges pending against any of the Releasees.

     3. MR. GILLIS acknowledges and agrees that in the absence of this Agreement, upon the
Termination Date he would be solely entitled to the amounts and benefits provided for under the
terms of the Employment Agreement. In lieu of the amounts and benefits provided under the
Employment Agreement, and in full consideration of MR. GILLIS’s execution of this Agreement, and
his agreement to be legally bound by its terms, NUCRYST agrees to make the

-4-

 

following payments and fulfill the following promises after receipt by NUCRYST of MR. GILLIS’S
signature on this Agreement, and after the expiration of the revocation period set forth in
paragraph 13(e) when this Agreement becomes final and binding:

          (a) pay MR. GILLIS a lump sum payment of $295,000.00, less applicable tax withholding and
deductions within thirty (30) days after the expiration of the revocation period set forth in
paragraph 13(e);

          (b) pay MR. GILLIS the lump sum amount of $150,000.00, less applicable tax withholding and
deductions, within thirty days after the expiration of the Transition Period provided that MR.
GILLIS fulfills his promises and obligations as set forth in paragraph 2(b) herein with regard to
the Transition Period, as well his other undertakings in this Agreement, including but not limited
to his continuing obligation to abide by Sections 9 and 10 of the Employment Agreement and the
post-employment restrictions contained in the Confidentiality Agreement, and his obligations under
paragraph 10 of this Agreement; MR. GILLIS understands and agrees that he will not be entitled to
receive the payment set forth in this paragraph 3(b) if he fails to fulfill his promises and
obligations as set forth in paragraph 2(b) herein with regard to the Transition Period, as well his
other undertakings in this Agreement, including but not limited to his continuing obligation to
abide by Sections 9 and 10 of the Employment Agreement and the post-employment restrictions
contained in the Confidentiality Agreement, and his obligations under paragraph 10 of this
Agreement;

          (c) reimburse MR. GILLIS for the after-tax cost of the COBRA premium payments incurred by MR.
GILLIS in connection with his group medical insurance coverage during the 18-month period following
the Termination Date; provided that MR. GILLIS elects to continue his group medical insurance
coverage pursuant to COBRA and executes this

-5-

 

Agreement; and provided, further, that NUCRYST’s obligation to reimburse MR. GILLIS shall
cease as of the date MR. GILLIS becomes eligible to receive health insurance coverage from another
employer or recipient of MR. GILLIS’s services (and provided, further, that such entitlement shall
be determined without regard to any individual waivers or other similar arrangements); NUCRYST will
make such reimbursement upon proof of payment;

          (d) permit MR. GILLIS to remain covered by NUCRYST’s directors and officers liability
insurance policy to the same extent as is provided to those persons who are members of NUCRYST’s
board of directors for a period of twenty-for (24) months after the Termination Date;

          (e) pay MR. GILLIS the lump sum amount of $5,000.00, less applicable tax withholding and
deductions, within thirty (30) days after the expiration of the revocation period set forth in
paragraph 13(e), which represents payment to MR. GILLIS in full reimbursement for all other
benefits MR. GILLIS was receiving as of the Termination Date, including, but not limited to,
regular and supplemental disability insurance and life insurance; and

          (f) allow Mr. Gillis to convert to a personal policy any disability or life insurance policies
that are so convertible, in accordance with the terms of such policies, provided that MR. GILLIS
shall be responsible for any premiums and conversion costs that may be due on such policies after
the Termination Date.

     4. MR. GILLIS represents that he has returned all property of NUCRYST including, but not
limited to, keys, files, records (and copies thereof), computer hardware and software, cellular
phones, pagers, which are in his possession or control, with the sole exceptions that MR. GILLIS
may continue his cellular phone service at his sole expense, and may purchase his desktop computer
and Blackberry from NUCRYST at current market value agreed to by the

-6-

 

parties after any and all NUCRYST information or data has been permanently removed from such
computer. MR. GILLIS further agrees to leave intact all electronic documents of NUCRYST, including
those which he developed or helped to develop during his employment. MR. GILLIS represents and
agrees that after the Termination Date, he will continue to abide by the post-employment
restrictions set forth in the Confidentiality Agreement and in Sections 9 and 10 of the Employment
Agreement, and that his obligations under the Confidentiality Agreement and under Sections 9 and 10
of the Employment Agreement survive the termination of his employment for NUCRYST.

     5. Except as expressly set forth in paragraphs 1(a) and 3 of this Agreement, MR. GILLIS
expressly agrees that he has been paid all remuneration owed to him by NUCRYST or Releasees as a
result of his employment with NUCRYST, the termination of that employment, the Employment
Agreement, the termination of the Employment Agreement, or for any other reason, including but not
limited to all accrued salary, wages, perquisites, variable pay, vacation pay, bonus pay,
profit-sharing, stock options, restricted stock award units, stock, expenses, termination benefits,
special incentive payments, or any other compensation, with the sole exception of any accrued
benefits under any qualified retirement plan maintained by NUCRYST in which MR. GILLIS has
participated, and that NUCRYST and Releasees do not have, and will not have, any obligation to
provide MR. GILLIS at any time in the future with any other payments, benefits, or consideration.
MR. GILLIS further represents and agrees that he has been provided with all notice due him under
his Employment Agreement.

     6. Except as expressly set forth herein, the parties hereto acknowledge that the undertakings
of each of the parties herein are expressly contingent upon the fulfillment and satisfaction of the
obligations of the other party as set forth herein.

-7-

 

     7. MR. GILLIS acknowledges and agrees that this Agreement is not and shall not be construed to
be an admission of any violation of any federal, state or local statute, regulation or law, or of
any duty owed by Releasees to MR. GILLIS, or of any wrongdoing to MR. GILLIS by Releasees, and that
this Agreement is made voluntarily to provide an amicable conclusion of his employment relationship
with NUCRYST.

     8. MR. GILLIS agrees, covenants and promises to keep the terms of this Agreement confidential
and not to take any steps to publicize the fact or terms of this Agreement, even if this Agreement
is disclosed by NUCRYST as part of its reporting obligations. MR. GILLIS represents that he has
not communicated or disclosed, and will not hereafter communicate, discuss or disclose, the terms
of this Agreement to any persons except, as he may be required by local, state or federal law or
regulation or by compulsory process of law, and provided that in case of such requirement he shall
notify NUCRYST within forty-eight (48) hours of such requirement in writing, and except for
disclosures to members of his immediate family, his attorney, and his accountant or tax advisor,
each of whom shall be informed of this confidentiality obligation and shall be bound by its terms.
In response to inquiries about the fact of his termination, or the fact or terms of this Agreement,
MR. GILLIS agrees that he will respond to such inquiries by stating that “the details of the
separation is confidential but it is related to a change in strategic direction, is amicable and
there is a severance package.” MR. GILLIS agrees that he will say nothing negative or unfavorable
about NUCRYST, or NUCRYST’s board of directors or management, concerning the fact of his
termination or the terms of this Agreement, and he will in all respects adhere to the
confidentiality provisions set forth in this paragraph.

-8-

 

     9. MR. GILLIS agrees and covenants that without the written consent of the Chairman of the
Board of NUCRYST, or by written invitation by a member of the board of directors, MR. GILLIS will
not enter upon or otherwise gain access to NUCRYST’s physical properties or databases after the
Termination Date. MR. GILLIS further covenants that he will not take any other action which has
the intent or effect of bringing harm to NUCRYST, its businesses, properties, management, directors
or affiliates. Without limiting the foregoing, MR. GILLIS agrees not to interfere in any manner
with NUCRYST’s relationships with its customers, suppliers, stockholders or employees.

     10. MR. GILLIS agrees and covenants not to disparage or to make any statement reflecting
negatively on NUCRYST or any other Releasee, or any product or service offered by NUCRYST or
Releasees, publicly or privately. NUCRYST agrees and covenants that it will use its reasonable
best efforts to ensure that the members of the board of directors of NUCRYST and the executive
officers of NUCRYST will not disparage or make any statement reflecting negatively on MR. GILLIS,
publicly or privately. For purposes of this paragraph 10, NUCRYST shall mean NUCRYST and any
person or entity, which is a subsidiary of, controlling or controlled by or under common control
with NUCRYST. Nothing in this paragraph shall preclude MR. GILLIS or NUCRYST from communicating or
testifying truthfully to the extent expressly required or protected by law, as a party in
litigation, by the proper inquiry of a state or federal governmental agency, by a subpoena to
testify issued by a court of competent jurisdiction, or in any action to enforce the terms of this
Agreement. Nothing in this paragraph shall preclude any communications internal to NUCRYST, nor
shall this Paragraph preclude NUCRYST or MR. GILLIS from communicating in confidence to its or his
attorneys, who shall be informed of this confidentiality obligation and shall be bound by its
terms.

-9-

 

     11. This Agreement constitutes the entire agreement between MR. GILLIS and NUCRYST with
respect to the subject matter hereof and supersedes and replaces any and all prior agreements or
understandings, whether written or oral, between the parties, including the Employment Agreement,
except that MR. GILLIS’S Confidentiality Agreement, 1999 Option Agreement and the Amendment to the
1999 Option Agreement, 2002 Option Agreement, 2003 Option Agreement, 2007 Option Agreement and RSU
Agreement, as well as his post-employment obligations under Sections 9 and 10 of the Employment
Agreement, continue in force and effect and shall survive the termination of the Employment
Agreement and the termination of MR. GILLIS’S employment, and are made a part of this Agreement by
reference as if set forth fully herein. MR. GILLIS acknowledges that neither NUCRYST, Releasees,
nor their directors, employees, agents or attorneys, have made any promise, representation or
warranty whatsoever, either express or implied, written or oral, other than the express written
representations herein. This Agreement may not be altered, amended, modified, or otherwise changed
in any respect except by another written agreement signed by both MR. GILLIS and NUCRYST.

     12. MR. GILLIS acknowledges that breach by him of any of the covenants or provisions set forth
herein, including a breach of his obligations under the Confidentiality Agreement or Sections 9 and
10 of the Employment Agreement, would cause NUCRYST severe and irreparable harm. Accordingly, in
the event of an actual or threatened breach by MR. GILLIS of any of the covenants or provisions set
forth herein, in the Confidentiality Agreement or in Sections 9 and 10 of the Employment Agreement,
NUCRYST will be entitled to seek an injunction restraining MR. GILLIS from violating such covenants
or provisions without the posting of a bond. The seeking of any such injunction shall not affect
NUCRYST’s right to seek

-10-

 

and obtain damages on account of any such actual or threatened breach of the covenants or
provisions of this Agreement, the Employment Agreement or the Confidentiality Agreement. MR.
GILLIS also shall be responsible to pay the costs and expenses to NUCRYST, including attorneys’
fees, arising out of the commission by MR. GILLIS of any breach of said covenants. In the event
that MR. GILLIS breaches his obligations under Section 9 of the Employment Agreement, in addition
to any other remedies that may be available to NUCRYST, MR. GILLIS shall forthwith repay to NUCRYST
a percentage of the total compensation paid to MR. GILLIS pursuant to paragraphs 3(a), (b) and (e)
of this Agreement equal to X/12, where X equals 12 less the number of months from the Termination
Date to the date of MR. GILLIS’S breach of Section 9; and, MR. GILLIS shall no longer be entitled
to receive the benefits as provided for in paragraphs 3(c), (d) and (f) of this Agreement.

     13. MR. GILLIS hereby certifies that:

          (a) he has read the terms of this Agreement, and that he understands its terms and effects,
including the fact that he has agreed to release and forever discharge Releasees from any legal
action arising out of his employment relationship with NUCRYST, the terms and conditions of that
employment relationship, and the termination of that employment relationship;

          (b) he has signed this Agreement voluntarily and knowingly in exchange for the consideration
described herein, which he acknowledges is adequate and satisfactory to him;

          (c) the payments, benefits, promises and undertakings performed, and to be performed, as set
forth in this Agreement exceed and are greater than the payments and benefits, if any, to which he
would have been entitled had he not executed this Agreement;

          (d) he has been informed that he has twenty-one (21) calendar days to consider whether or not
to sign this Agreement, and has signed on the date indicated below after

-11-

 

concluding that this Agreement is satisfactory; if MR. GILLIS elects not to take the full
twenty-one (21) days to consider this Agreement, he agrees that he has done so knowingly,
voluntarily, and with full understanding that he is waiving a statutory right to consider this
Agreement for twenty-one (21) days.;

          (e) he has been informed that he has the right to revoke this Agreement for a period of seven
(7) calendar days following his execution of this Agreement by giving written notice to NUCRYST to
the attention of President, NUCRYST Pharmaceuticals Corp., 50 Audubon Road, Suite B, Wakefield,
Massachusetts 01880, and that this Agreement shall not be effective, enforceable, final or binding
until this seven (7) day period has expired;

          (f) he understands and agrees that if he revokes this Agreement, pursuant to paragraph 13(e),
that NUCRYST shall have no obligation to provide MR. GILLIS with any of the payments or benefits
provided in paragraph 3 of this Agreement other than the amounts that would be required per the
Terms of his Employment Agreement, and that no other payments or benefits will be provided in lieu
of such;

          (g) he has been and is hereby advised by NUCRYST to consult with an attorney prior to signing
this Agreement, and he has in fact done so with his counsel of choice.

     14. This Agreement shall be governed, interpreted and enforced by and under the laws of the
Commonwealth of Massachusetts, without regard to choice of law principles, except where federal law
controls. This Agreement shall be enforced by the federal or state courts located in the
Commonwealth of Massachusetts. MR. GILLIS consents to the personal jurisdiction of such courts,
and waives any jurisdiction or venue defenses otherwise available to him.

-12-

 

     15. Should any term or provision of this Agreement be declared illegal, invalid or
unenforceable by any court of competent jurisdiction and if such provision cannot be modified to be
enforceable, such provision shall immediately become null and void, leaving the remainder of this
Agreement in full force and effect. The language of all parts of this Agreement shall in all cases
be construed as a whole, according to its fair meaning, and not strictly for or against any of the
parties.

     16. MR. GILLIS agrees that, for a period of twelve (12) months after the Termination Date, he
shall notify NUCRYST in writing of any change of residence address and of any subsequent employment
(stating the name and address of the employer and providing a description of the title and duties
of the position) or of any other business activity.

     17. Any notice required to be given to any party under any provision of this Agreement shall
be made in writing, by first class mail, to the following addresses:

          To NUCRYST: to the attention of President, NUCRYST Pharmaceuticals Corp., 50 Audubon Road,
Suite B, Wakefield, Massachusetts 01880.

          To MR. GILLIS: to the attention of Scott H. Gillis, 80 Alford Circle, Concord, MA 01742.

     IN WITNESS WHEREOF, and intending to be legally bound hereby, the parties have executed the
foregoing Confidential Separation Agreement and General Release as of the date written above.

	 	 	 	 	 	 	 	 	 	 	 
	WITNESS:	 	/s/ Lindsay M. Gillis	 	 	 	/s/ Scott H. Gillis	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Scott H. Gillis	 	 

-13-

 

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	NUCRYST PHARMACEUTICALS CORP.
	 
	 	 	 	 	 	 	 	 	 	 
	WITNESS:

	 	/s/ Carolyn Kessinger
	 	 	 	By:
	 	/s/ Thomas E. Gardner	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Name:
	 	Thomas E. Gardner	 	 
	 

	 	 	 	 	 	Title:
	 	Chairman & CEO	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	NUCRYST PHARMACEUTICALS INC.
	 
	 	 	 	 	 	 	 	 	 	 
	WITNESS:

	 	/s/ Carolyn Kessinger
	 	 	 	By:
	 	/s/ Thomas E. Gardner	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Name:
	 	Thomas E. Gardner	 	 
	 

	 	 	 	 	 	Title:
	 	Chairman & CEO	 	 

-14-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}]]